ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LNTH Lantheus Holdings Inc

78.27
10.88 (16.14%)
After Hours
Last Updated: 23:58:49
Delayed by 15 minutes
Share Name Share Symbol Market Type
Lantheus Holdings Inc NASDAQ:LNTH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.88 16.14% 78.27 77.70 78.29 79.25 74.825 75.00 3,707,004 23:58:49

Lantheus Holdings, Inc. to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

13/09/2017 9:02pm

Business Wire


Lantheus (NASDAQ:LNTH)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Lantheus Charts.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), today announced that Mary Anne Heino, President and Chief Executive Officer, and Jack Crowley, Chief Financial Officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 at 1:40 p.m. Eastern Time. The conference will be held at the InterContinental New York Barclay Hotel in New York City.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Lantheus Holdings, Inc.Meara Murphy, 978-671-8508Director, Investor Relations & Corporate CommunicationsorGary Santo, 978-671-8960Head of Capital Markets & Investor Relations

1 Year Lantheus Chart

1 Year Lantheus Chart

1 Month Lantheus Chart

1 Month Lantheus Chart

Your Recent History

Delayed Upgrade Clock